{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:13:33Z","timestamp":1792725213537,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.intimp.2025.115021","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T16:46:16Z","timestamp":1749746776000},"page":"115021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Psoriasis unveiled: The cellular ballet, molecular symphony, and genetic puzzle"],"prefix":"10.1016","volume":"161","author":[{"given":"Ankita","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"issue":"9","key":"10.1016\/j.intimp.2025.115021_bb0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199503023320907","article-title":"Treatment of psoriasis","volume":"332","author":"Greaves","year":"1995","journal-title":"New England J. Med."},{"issue":"19","key":"10.1016\/j.intimp.2025.115021_bb0015","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.intimp.2025.115021_bb0020","first-page":"953","article-title":"Inverse psoriasis: from diagnosis to current treatment options","volume":"31","author":"Micali","year":"2019","journal-title":"Clin. cosmetic Investigational Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115021_bb0025","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1365-2133.2001.04505.x","article-title":"A systematic review of treatments for guttate psoriasis","volume":"145","author":"Chalmers","year":"2001","journal-title":"British J. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115021_bb0030","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","article-title":"An update on generalized pustular psoriasis","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115021_bb0035","series-title":"Erythrodermic psoriasis: pathophysiology and current treatment perspectives","first-page":"93","author":"Singh","year":"2016"},{"issue":"4","key":"10.1016\/j.intimp.2025.115021_bb0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000018026","article-title":"Scalp psoriasis, clinical presentations and therapeutic management","volume":"197","author":"Van de Kerkhof","year":"1998","journal-title":"Dermatology"},{"issue":"7564","key":"10.1016\/j.intimp.2025.115021_bb0045","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/bmj.333.7564.380","article-title":"Psoriasis and its management","volume":"333","author":"Smith","year":"2006","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.intimp.2025.115021_bb0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investigative Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0055","first-page":"79","article-title":"A brief summary of clinical types of psoriasis","volume":"3","author":"Sarac","year":"2016","journal-title":"Northern Clinics Istanbul."},{"issue":"9","key":"10.1016\/j.intimp.2025.115021_bb0060","article-title":"Types of psoriasis and their effects on the immune system","volume":"14","author":"Dhabale","year":"2022","journal-title":"Cureus"},{"issue":"5S","key":"10.1016\/j.intimp.2025.115021_bb0065","first-page":"18","article-title":"Psoriasis risk factors and triggers","volume":"102","author":"Lee","year":"2018","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2004.02310.x","article-title":"Immunopathogenic mechanisms in psoriasis","volume":"135","author":"Gudjonsson","year":"2004","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115021_bb0080","first-page":"1","article-title":"The Immunology of Psoriasis\u2014Current Concepts in Pathogenesis","volume":"20","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115021_bb0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000495291","article-title":"Psoriasis: keratinocytes or immune cells\u2013which is the trigger?","volume":"235","author":"Benhadou","year":"2019","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.intimp.2025.115021_bb0090","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/1346-8138.15184","article-title":"Dendritic cells: The driver of psoriasis","volume":"47","author":"Wang","year":"2020","journal-title":"J. Dermatol."},{"issue":"13","key":"10.1016\/j.intimp.2025.115021_bb0095","article-title":"Dendritic cells and macrophages in the pathogenesis of psoriasis","volume":"28","author":"Kamata","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115021_bb0100","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","article-title":"Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells","volume":"208","author":"Ghoreschi","year":"2011","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1468-3083.2003.00720.x","article-title":"The role of T cells in psoriasis","volume":"17","author":"Prinz","year":"2003","journal-title":"J. European Academy Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115021_bb0110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/cmi.2012.15","article-title":"New insights of T cells in the pathogenesis of psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115021_bb0115","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.clindermatol.2007.08.012","article-title":"Immunopathogenesis and role of T cells in psoriasis","volume":"25","author":"Ghoreschi","year":"2007","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.intimp.2025.115021_bb0120","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12026-020-09149-1","article-title":"The role of Th17 cells in psoriasis","volume":"68","author":"Li","year":"2020","journal-title":"Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0125","article-title":"T helper cell subsets in clinical manifestations of psoriasis","volume":"2016","author":"Diani","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.intimp.2025.115021_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res. & Therapy."},{"issue":"5","key":"10.1016\/j.intimp.2025.115021_bb0135","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J. Investigative Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115021_bb0140","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.intimp.2015.11.005","article-title":"Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-\u03b1 treatment in psoriasis","volume":"29","author":"Luan","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0145","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/sji.12404","article-title":"Characterization of Th17 and FoxP3+ Treg cells in paediatric psoriasis patients","volume":"83","author":"Zhang","year":"2016","journal-title":"Scand. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clim.2009.11.008","article-title":"Increased Th17 cells are accompanied by FoxP3+ Treg cell accumulation and correlated with psoriasis disease severity","volume":"135","author":"Zhang","year":"2010","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115021_bb0155","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2013.477","article-title":"Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis","volume":"134","author":"Villanova","year":"2014","journal-title":"J. Investigative Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115021_bb0160","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fimmu.2020.00242","article-title":"Innate lymphocytes in psoriasis","volume":"21","author":"Polese","year":"2020","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2025.115021_bb0165","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.3390\/ijms21186604","article-title":"Role of innate immune cells in psoriasis","volume":"21","author":"Sato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2025.115021_bb0170","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/jid.2014.146","article-title":"Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR+ ILC3 in lesional skin and blood of psoriasis patients","volume":"134","author":"Teunissen","year":"2014","journal-title":"J. Investigative Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2133.2003.05319.x","article-title":"Circulating natural killer cells in psoriasis","volume":"149","author":"Cameron","year":"2003","journal-title":"British J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115021_bb0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000328011","article-title":"Natural killer cells in psoriasis","volume":"3","author":"Tobin","year":"2011","journal-title":"J. Innate Immunity"},{"key":"10.1016\/j.intimp.2025.115021_bb0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00403-002-0349-4","article-title":"Natural killer and natural killer-T cells in psoriasis","volume":"294","author":"Cameron","year":"2002","journal-title":"Archives Dermatol Res."},{"issue":"177","key":"10.1016\/j.intimp.2025.115021_bb0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2015.10.004","article-title":"Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production","volume":"1","author":"Dunphy","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115021_bb0195","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00403-008-0874-x","article-title":"Is there a role for mast cells in psoriasis?","volume":"300","author":"Harvima","year":"2008","journal-title":"Archives Dermatol. Res."},{"issue":"24","key":"10.1016\/j.intimp.2025.115021_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413252","article-title":"Psychological stress, mast cells, and psoriasis\u2014is there any relationship?","volume":"22","author":"Wo\u017aniak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115021_bb0205","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00513956","article-title":"Mast cells in the initial stages of psoriasis","volume":"280","author":"Toruniowa","year":"1988","journal-title":"Arch. Dermatol. Res."},{"issue":"13","key":"10.1016\/j.intimp.2025.115021_bb0210","article-title":"Dendritic cells and macrophages in the pathogenesis of psoriasis","volume":"28","author":"Kamata","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115021_bb0215","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1172\/JCI29441","article-title":"Misbehaving macrophages in the pathogenesis of psoriasis","volume":"116","author":"Clark","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0220","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3709749","article-title":"Role of neutrophils in psoriasis","volume":"2020","author":"Wang","year":"2020","journal-title":"J Immunol Res"},{"issue":"10","key":"10.1016\/j.intimp.2025.115021_bb0225","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3389\/fimmu.2019.02376","volume":"9","author":"Chiang","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115021_bb0230","doi-asserted-by":"crossref","first-page":"13241","DOI":"10.1096\/fj.201900642R","article-title":"Keratinocyte exosomes activate neutrophils and enhance skin inflammation in psoriasis","volume":"33","author":"Jiang","year":"2019","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.intimp.2025.115021_bb0235","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/DAD.0000000000001303","article-title":"Eosinophils among the histologic features of psoriasis","volume":"41","author":"Penn","year":"2019","journal-title":"Am. J. Dermatopathol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115021_bb0240","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/cup.13042","article-title":"Eosinophils are rare in biopsy specimens of psoriasis vulgaris","volume":"44","author":"Rosa","year":"2017","journal-title":"J. Cutan. Pathol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115021_bb0245","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1398-9995.2011.02570.x","article-title":"Basophil recruitment and activation in inflammatory skin diseases","volume":"66","author":"Ito","year":"2011","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.intimp.2025.115021_bb0250","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2017.07.003","article-title":"Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis","volume":"88","author":"Mashiko","year":"2017","journal-title":"J. Dermatological Sci."},{"issue":"6","key":"10.1016\/j.intimp.2025.115021_bb0255","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2025.115021_bb0260","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"2","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2014.02.006","article-title":"The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants","volume":"74","author":"Sugiura","year":"2014","journal-title":"J. Dermatol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0270","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0275","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J. Am. Academy Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115021_bb0280","first-page":"518","article-title":"Research in practice: IL-22 and IL-20: significance for epithelial homeostasis and psoriasis pathogenesis. JDDG","volume":"9","author":"Sabat","year":"2011","journal-title":"J. der Deutschen Dermatologischen Gesellschaft"},{"issue":"6","key":"10.1016\/j.intimp.2025.115021_bb0285","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cytogfr.2010.10.007","article-title":"Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease","volume":"21","author":"Ouyang","year":"2010","journal-title":"Cytokine & Growth Ractor Rev."},{"issue":"204","key":"10.1016\/j.intimp.2025.115021_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006245","article-title":"IL-29 is produced by TH17 cells and mediates the cutaneous antiviral competence in psoriasis","volume":"5","author":"Wolk","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115021_bb0295","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11154-016-9381-0","article-title":"Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations","volume":"17","author":"Wolk","year":"2016","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.intimp.2025.115021_bb0300","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12016-012-8306-2","article-title":"Cytokine-based therapy in psoriasis","volume":"44","author":"Mitra","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115021_bb0305","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines","volume":"9","author":"Fitch","year":"2007","journal-title":"Curr. Rheumatol. Rep."},{"issue":"10","key":"10.1016\/j.intimp.2025.115021_bb0310","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J. European Academy Dermatol. Venereol."},{"issue":"10275","key":"10.1016\/j.intimp.2025.115021_bb0315","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0320","first-page":"264","article-title":"TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis","volume":"1","author":"Victor","year":"2002","journal-title":"J. Drugs Dermatol: JDD."},{"issue":"5","key":"10.1016\/j.intimp.2025.115021_bb0325","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clindermatol.2003.08.015","article-title":"Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-\u03b1) blockade in psoriasis and psoriatic arthritis","volume":"21","author":"Victor","year":"2003","journal-title":"Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115021_bb0330","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series","volume":"34","author":"Cohen","year":"2007","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0335","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","article-title":"Elevated tumour necrosis factor-alpha (TNF-\u03b1) biological activity in psoriatic skin lesions","volume":"96","author":"Ettehadi","year":"1994","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0340","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/ijms25010167","article-title":"Mechanistic investigation of WWOX function in NF-kB-induced skin inflammation in psoriasis","volume":"25","author":"Shin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.115021_bb0345","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ajhg.2012.03.013","article-title":"Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis","volume":"90","author":"Jordan","year":"2012","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.intimp.2025.115021_bb0350","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/ijd.12050","article-title":"Role of NF-\u03baB in the pathogenesis of psoriasis elucidated by its staining in skin biopsy specimens","volume":"53","author":"Moorchung","year":"2014","journal-title":"Int. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0355","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/21655979.2020.1863015","article-title":"Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-\u03baB and MAPKs signaling pathways","volume":"12","author":"Liu","year":"2021","journal-title":"Bioengineered"},{"issue":"23","key":"10.1016\/j.intimp.2025.115021_bb0360","doi-asserted-by":"crossref","first-page":"13004","DOI":"10.3390\/ijms222313004","article-title":"Genetic variants of the NF-\u03baB pathway: unraveling the genetic architecture of psoriatic disease","volume":"22","author":"Queiro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115021_bb0365","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2147\/DDDT.S447780","article-title":"RNA-based antipsoriatic gene therapy: an updated review focusing on evidence from animal models","volume":"31","author":"Lin","year":"2024","journal-title":"Drug Design, Develop. Therapy"},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0370","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/14712598.4.1.75","article-title":"Antisense oligonucleotide treatments for psoriasis","volume":"4","author":"White","year":"2004","journal-title":"Exp. Opinion Biol. Therapy."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-7258(01)00133-4","article-title":"Antisense oligonucleotides in cutaneous therapy","volume":"90","author":"Wraight","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.115021_bb0380","series-title":"Development of novel antisense oligonucleotide molecules towards tackling rare and acquired diseases","author":"Raguraman","year":"2023"},{"key":"10.1016\/j.intimp.2025.115021_bb0385","first-page":"35","article-title":"RNA interference targeting interstitial collagenase is a potential therapeutic tool to treat psoriasis","volume":"3","author":"Mezentsev","year":"2017","journal-title":"Bull. Russian State Med. Univ."},{"issue":"24","key":"10.1016\/j.intimp.2025.115021_bb0390","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1097\/CM9.0000000000001197","article-title":"Small interfering RNA targeting of keratin 17 reduces inflammation in imiquimod-induced psoriasis-like dermatitis","volume":"133","author":"Xiao","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.intimp.2025.115021_bb0395","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00403-013-1379-9","article-title":"Identifying targets for topical RNAi therapeutics in psoriasis: assessment of a new in vitro psoriasis model","volume":"305","author":"Bracke","year":"2013","journal-title":"Archives Dermatol. Res."},{"issue":"17","key":"10.1016\/j.intimp.2025.115021_bb0400","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.4103\/0366-6999.239297","article-title":"Effect of RNA interference targeting STAT3 gene combined with ultrasonic irradiation and SonoVue microbubbles on proliferation and apoptosis in keratinocytes of psoriatic lesions","volume":"131","author":"Ran","year":"2018","journal-title":"Chin. Med. J."},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0405","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0625.2010.01066.x","article-title":"The anti-apoptotic protein G1P3 is overexpressed in psoriasis and regulated by the non-coding RNA","volume":"19","author":"Szegedi","year":"2010","journal-title":"PRINS. Exp Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115021_bb0410","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe2888","article-title":"Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders","volume":"7","author":"Wan","year":"2021","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0415","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/ijms23031337","article-title":"Genome editing using CRISPR-Cas9 and autoimmune diseases: A comprehensive review","volume":"23","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2025.115021_bb0420","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.jid.2018.07.016","article-title":"Genome editing of human primary keratinocytes by CRISPR\/Cas9 reveals an essential role of the NLRP1 inflammasome in UVB sensing","volume":"138","author":"Fenini","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"16","key":"10.1016\/j.intimp.2025.115021_bb0425","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl4336","article-title":"Dual-responsive nanocarriers for efficient cytosolic protein delivery and CRISPR-Cas9 gene therapy of inflammatory skin disorders","volume":"10","author":"Tan","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2025.115021_bb0430","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/ITT.S458800","article-title":"Targeted siRNA therapy for psoriasis: Translating preclinical potential into clinical treatments","volume":"31","author":"Zhao","year":"2024","journal-title":"ImmunoTargets Therapy"},{"issue":"268","key":"10.1016\/j.intimp.2025.115021_bb0435","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2017.10.034","article-title":"Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis","volume":"28","author":"Nemati","year":"2017","journal-title":"J. Control. Release"},{"issue":"338","key":"10.1016\/j.intimp.2025.115021_bb0440","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2021.08.039","article-title":"TNF\u03b1 siRNA delivery by nanoparticles and photochemical internalization for psoriasis topical therapy","author":"Suzuki","year":"2021","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.intimp.2025.115021_bb0445","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/exd.13414","article-title":"Towards the development of a RNA i-based topical treatment for psoriasis: Proof-of-concept in a 3D psoriasis skin model","volume":"27","author":"Desmet","year":"2018","journal-title":"Exp. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0450","doi-asserted-by":"crossref","first-page":"333","DOI":"10.25259\/IJDVL_470_19","article-title":"Novel drug delivery strategies and gene therapy regimen as a promising perspective for management of psoriasis","volume":"87","author":"Sawarkar","year":"2021","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115021_bb0455","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.3390\/ijms24076390","article-title":"The role of adipokines in the pathogenesis of psoriasis","volume":"24","author":"Kie\u0142bowski","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2025.115021_bb0460","first-page":"s12015","article-title":"Current gene therapy using viral vectors for chronic pain","volume":"13","author":"Guedon","year":"2015","journal-title":"Mol. Pain"},{"key":"10.1016\/j.intimp.2025.115021_bb0465","series-title":"Britta Engelhardt","author":"Amann-Vesti","year":"2025"},{"issue":"11","key":"10.1016\/j.intimp.2025.115021_bb0470","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41419-023-06234-9","article-title":"Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 Pathway activation and attenuating inflammatory signaling","volume":"14","author":"Ma","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115021_bb0475","article-title":"Novel insight into MDA-7\/IL-24: A potent therapeutic target for autoimmune and inflammatory diseases","volume":"20","author":"Feng","year":"2024","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115021_bb0480","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jmb.2008.07.046","article-title":"IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22","volume":"382","author":"Wu","year":"2008","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0485","doi-asserted-by":"crossref","DOI":"10.5501\/wjv.v13.i1.89934","article-title":"Herpes simplex keratitis: A brief clinical overview","volume":"13","author":"Musa","year":"2024","journal-title":"World J. Virol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115021_bb0490","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41419-023-06234-9","article-title":"Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 Pathway activation and attenuating inflammatory signaling","volume":"14","author":"Ma","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115021_bb0495","article-title":"Novel insight into MDA-7\/IL-24: A potent therapeutic target for autoimmune and inflammatory diseases","volume":"20","author":"Feng","year":"2024","journal-title":"Clin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115021_bb0500","first-page":"1154","article-title":"PP2Ac\u03b1 regulates epidermal cell proliferation via the EGFR\/AKT\/mTOR pathway in psoriasis-like skin lesions caused by PPP2CA deficiency","volume":"31","author":"Tao","year":"2022","journal-title":"Exp. Dermatol."},{"issue":"17","key":"10.1016\/j.intimp.2025.115021_bb0505","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156501","article-title":"Human \u03b2-defensin-3 attenuates atopic dermatitis\u2013like inflammation through autophagy activation and the aryl hydrocarbon receptor signaling pathway","volume":"132","author":"Peng","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115021_bb0510","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10456-017-9561-x","article-title":"CXCL10 suppression of hem-and lymph-angiogenesis in inflamed corneas through MMP13","volume":"20","author":"Gao","year":"2017","journal-title":"Angiogenesis"},{"issue":"23","key":"10.1016\/j.intimp.2025.115021_bb0515","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.2174\/1381612824666180807120017","article-title":"Current non-viral siRNA delivery systems as a promising treatment of skin diseases","volume":"24","author":"Rosa","year":"2018","journal-title":"Curr. Pharmaceutical Design"},{"key":"10.1016\/j.intimp.2025.115021_bb0520","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/ITT.S458800","article-title":"Targeted siRNA therapy for psoriasis: Translating preclinical potential into clinical treatments","volume":"31","author":"Zhao","year":"2024","journal-title":"ImmunoTargets Therapy"},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0939-6411(03)00155-3","article-title":"Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy","volume":"57","author":"Mansouri","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.intimp.2025.115021_bb0530","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/pharmaceutics16040449","article-title":"Recent approaches for the topical treatment of psoriasis using nanoparticles","volume":"16","author":"Bodn\u00e1r","year":"2024","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.intimp.2025.115021_bb0535","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/cbin.11841","article-title":"siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review","volume":"46","author":"Sargazi","year":"2022","journal-title":"Cell Biol. Int."},{"issue":"13","key":"10.1016\/j.intimp.2025.115021_bb0540","article-title":"Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis","volume":"22","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115021_bb0545","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/polym10040444","article-title":"Chitosan in non-viral gene delivery: Role of structure, characterization methods, and insights in cancer and rare diseases therapies","volume":"10","author":"Santos-Carballal","year":"2018","journal-title":"Polymers"},{"issue":"23","key":"10.1016\/j.intimp.2025.115021_bb0550","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.2174\/1381612824666180807120017","article-title":"Current non-viral siRNA delivery systems as a promising treatment of skin diseases","volume":"24","author":"Rosa","year":"2018","journal-title":"Curr. Pharmaceutical Design"},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0555","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/pharmaceutics17030283","article-title":"Topical Therapy in Psoriasis: Clinical Benefits, Advances in Novel Drug Delivery Strategies, and Gene Therapy Regimen","volume":"17","author":"Zhu","year":"2025","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.intimp.2025.115021_bb0560","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fneur.2020.00740","article-title":"Chitosan-based non-viral gene and drug delivery systems for brain cancer","volume":"30","author":"Lara-Velazquez","year":"2020","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115021_bb0565","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/cbin.11841","article-title":"siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review","volume":"46","author":"Sargazi","year":"2022","journal-title":"Cell Biol. Int."},{"issue":"4","key":"10.1016\/j.intimp.2025.115021_bb0570","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/polym10040444","article-title":"Chitosan in non-viral gene delivery: Role of structure, characterization methods, and insights in cancer and rare diseases therapies","volume":"10","author":"Santos-Carballal","year":"2018","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0575","first-page":"7099","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin. Nature","volume":"14","author":"Tang","year":"2023","journal-title":"Communications"},{"issue":"4","key":"10.1016\/j.intimp.2025.115021_bb0580","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/pharmaceutics16040449","article-title":"Recent approaches for the topical treatment of psoriasis using nanoparticles","volume":"16","author":"Bodn\u00e1r","year":"2024","journal-title":"Pharmaceutics"},{"issue":"13","key":"10.1016\/j.intimp.2025.115021_bb0585","article-title":"Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis","volume":"22","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.intimp.2025.115021_bb0590","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.2174\/1381612824666180807120017","article-title":"Current non-viral siRNA delivery systems as a promising treatment of skin diseases","volume":"24","author":"Rosa","year":"2018","journal-title":"Curr. Pharmaceutical Design"},{"issue":"7","key":"10.1016\/j.intimp.2025.115021_bb0595","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1101\/gr.267963.120","article-title":"Deep sequencing of 1320 genes reveals the landscape of protein-truncating variants and their contribution to psoriasis in 19,973 Chinese individuals","volume":"31","author":"Xu","year":"2021","journal-title":"Genome Res."},{"issue":"12","key":"10.1016\/j.intimp.2025.115021_bb0600","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/1346-8138.16914","article-title":"Expression of interleukin-36 receptor antagonist in a patient with generalized pustular psoriasis harboring the p. Pro82Leu variant in the IL36RN gene. The","volume":"50","author":"Mizukawa","year":"2023","journal-title":"J. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115021_bb0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025038","article-title":"Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q","volume":"6","author":"Pidasheva","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.intimp.2025.115021_bb0610","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygeno.2017.10.003","article-title":"dbGAPs: A comprehensive database of genes and genetic markers associated with psoriasis and its subtypes","volume":"110","author":"Aggarwal","year":"2018","journal-title":"Genomics"},{"issue":"6","key":"10.1016\/j.intimp.2025.115021_bb0615","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C* 06: 02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115021_bb0620","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/pharmaceutics16010111","article-title":"Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents","volume":"16","author":"Drakos","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2025.115021_bb0625","series-title":"Genetics of Psoriasis and Related Diseases","author":"Naldi","year":"2024"},{"issue":"3","key":"10.1016\/j.intimp.2025.115021_bb0630","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/pharmaceutics17030283","article-title":"Topical therapy in psoriasis: Clinical benefits, advances in novel drug delivery strategies, and gene therapy regimen","volume":"17","author":"Zhu","year":"2025","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.intimp.2025.115021_bb0635","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti\u2013IL-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115021_bb0640","series-title":"Method of treating psoriasis with anti-IL23 specific antibody","article-title":"Inventors; Janssen Biotech Inc, assignee","author":"Fitzgerald","year":"2021"},{"key":"10.1016\/j.intimp.2025.115021_bb0645","series-title":"OTEZLA\u00ae(APREMILAST) NOW AVAILABLE IN THE US FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS","author":"Newswire","year":"2024"},{"key":"10.1016\/j.intimp.2025.115021_bb0650","series-title":"Current Opinion in Investigational Drugs London, England: 2000","first-page":"216","volume":"2","author":"Yung RLEtanercept Immunex","year":"2001"},{"key":"10.1016\/j.intimp.2025.115021_bb0655","series-title":"National Center for Biotechnology Information","author":"PubChem [Internet]. Bethesda (MD): National Library of Medicine (US)","year":"2004"},{"key":"10.1016\/j.intimp.2025.115021_bb0660","unstructured":"Amgen Wins Patent Case on Otezla\u00ae (apremilast)| Amgen. 2021. (Accessed on 11\/6\/2025)."},{"key":"10.1016\/j.intimp.2025.115021_bb0665","unstructured":"Etanercept \u2013 Wikipedia. (Accessed on 11\/6\/2025)."},{"key":"10.1016\/j.intimp.2025.115021_bb0670","unstructured":"JNJ-77242113 \u2013 Wikipedia 2025. (Accessed on 11\/6\/2025)."},{"key":"10.1016\/j.intimp.2025.115021_bb0675","unstructured":"US8455035B2 - Plant seed oil - Google Patents. (Accessed on 11\/6\/2025)."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925010112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925010112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T19:56:59Z","timestamp":1775764619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925010112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":135,"alternative-id":["S1567576925010112"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115021","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis unveiled: The cellular ballet, molecular symphony, and genetic puzzle","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115021"}}